Alzheimer’s progression slowed by drug in major trial

Though the effect of Eisai and Biogen’s treatment was small, and reported side effects were serious, this is the first large clinical trial in which cognitive decline caused by Alzheimer’s has been delayed.

Photo: Steven Senne/AP/Ritzau Scanpix

Eisai Co. and partner Biogen Inc. said their drug significantly slowed Alzheimer’s disease, making it the first medicine to blunt progression of the most common dementia in a definitive, large-scale trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs